US government regulators have ordered a Silicon Valley genetic-testing startup funded by Google to halt sales of its product to consumers.
"FDA is concerned about the public health consequences of inaccurate results from the PGS device," the agency said Monday. "The main purpose of compliance with FDA's regulatory requirements is to ensure that the tests work."
In a statement, the Mountain View, California-based company said it was continuing to work to obtain approval from the FDA.
"We recognise that we have not met the FDA's expectations regarding time line and communication regarding our submission," Catherine Afarian, a spokeswoman for 23andMe, said in a statement.
"Our relationship with the FDA is extremely important to us and we are committed to fully engaging with them to address their concerns."
23andMe has been closely watched because of its role as a pioneer in the personal genetic-testing space - and because its founder, Anne Wojcicki, is the ex-wife of Google co-founder Sergey Brin. The pair only recently made their split public.
Google is one the firms that has provided venture capital to 23andMe.
The company sells a kit and service that promises to let users know whether they are at risk for certain diseases based on their DNA.
But according to the FDA, such a product constitutes a medical device that must be approved by the agency.
23andMe, which was founded six years ago, sought FDA approval last year in a series of applications. In its letter Monday, the FDA said 23andMe did not address "the issues described during previous interactions."
What will be the main motivation for humanity's future space endeavours?Related story: (See story)
The cost of losing nature